The Supreme Court will hold a hearing on Monday to consider whether drugmakers can settle patent lawsuits with generic-drug makers by making arrangements to block generics. "The continuing stream of monopoly profits is large enough to pay the generic competitors more than they could hope to earn if they entered the market at competitive prices," according to the Federal Trade Commission in a brief. Drugmakers are defending such deals to avert patent litigation, although the European Union, the U.S. Justice Department and more than 24 state attorneys general deem such deals illegal.

Full Story:

Related Summaries